JOURNAL OF THROMBOSIS AND THROMBOLYSIS, cilt.23, sa.1, ss.31-34, 2007 (SCI-Expanded)
Aims Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to patients with TE without malignancy and healthy control.